Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.31M | $2.08M | $317K | $0.00 | — | — |
| Revenue growth | — | -10.0% | -84.8% | -100.0% | — | — |
| Gross profit | $1.03M | $927K | $159K | $0.00 | — | — |
| Gross margin | 44.6% | 44.6% | 50.1% | — | — | — |
| Operating income | -$17.1M | -$33.9M | -$51.7M | -$58.4M | -$64.1M | -$59.4M |
| Operating margin | -739.0% | -1629.2% | -16325.8% | — | — | — |
| Net income | -$17.0M | -$33.5M | -$50.5M | -$53.5M | -$61.0M | -$56.0M |
| Net margin | -737.2% | -1612.3% | -15937.3% | — | — | — |
| EPS (diluted) | -$3.44 | -$2.46 | -$1.91 | -$1.88 | -$2.04 | -$1.27 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$14.6M | -$30.9M | -$44.1M | -$49.0M | -$55.0M | -$45.3M |
| Capital expenditures | $53.4K | $60.8K | $742K | $343K | $84.9K | $142K |
| Free cash flow | -$14.7M | -$30.9M | -$44.8M | -$49.3M | -$55.1M | -$45.5M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $37.1M | $74.9M | $72.6M | $59.4M | $36.1M | $129M |
| Total assets | $38.4M | $167M | $122M | $103M | $52.7M | $232M |
| Total liabilities | $2.80M | $10.7M | $12.5M | $12.0M | $11.3M | $13.5M |
| Shareholders' equity | -$22.5M | $156M | $110M | $90.6M | $41.4M | $218M |
| Retained earnings | -$25.7M | -$59.3M | -$110M | -$163M | -$224M | -$280M |
| Shares (wtd avg diluted) | 4.95M | 13.6M | 26.4M | 28.4M | 30.0M | 44.0M |
Every figure is extracted from Immuneering Corp’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.